Hyphens Pharma inks exclusive licensing deal for ustekinumab biosimilar
Hyphens Pharma International, Singapore’s leading specialty pharmaceutical and consumer healthcare group, says that its subsidiary, Hyphens Pharma Pte has signed an exclusive license and supply agreement with DKSH’s subsidiary, Favorex Pte to commercialize the ustekinumab biosimilar produced by Alvotech (SWX: DKSH), in Singapore, Malaysia, and the Philippines.
The proposed Ustekinumab biosimilar, which is undergoing clinical studies, is a human monoclonal antibody that targets interleukin-12 (“IL-12”) and interleukin-23 (IL-23) for the treatment of immune mediated disorders like plaque psoriasis, psoriatic arthritis and Crohn’s disease.
Biosimilar of J&J’s Stelara
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze